Clinical trial

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

NCT06430671

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-06-18

PhasePHASE1

Study timeline

Study start (actual)2024-06-18Date precision: day

Registry last updated2026-06-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)unresolved

Interventions

CLS12311 lowDRUG

CLS12311 mediumDRUG

CLS12311 highDRUG

uncoupled RBCsDRUG

Sponsors & collaborators

Cellerys AGlead sponsor

Novartiscollaborator

Scope International AGcollaborator

Tetec AGcollaborator

Jung Diagnostics GmbHcollaborator

Mapped research locations

PragueCzechia2 ZurichSwitzerland2 HamburgGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06430671 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.